Develop and distribute placental tissue allografts. Utilize the patented PURION process to create allografts. Now — the numbers.
This is an established company with proven profits.
Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $143.6M would still be left in the vault — a solid cushion for hard times.
The market pays 13.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 75% of them.
Analysts' average target sits 68% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 15% a year on average.
There is $166.1M in the vault; even if every debt were paid off, $143.6M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, MDXG sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: MDXG is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.